Critical Advantage of Sucralfate in Specific Populations

Mortality and Ventilator-Associated Pneumonia Advantage

In critically ill patients requiring stress ulcer prophylaxis, sucralfate demonstrates a mortality advantage over H2-receptor antagonists, with a reduced mortality odds ratio of 0.73 (95% CI 0.54-0.97) 1
Sucralfate is associated with a lower likelihood of developing ventilator-associated pneumonia (VAP) compared to H2-receptor antagonists, with a 35% lower likelihood of VAP and a significant reduction in VAP incidence (16.2% vs 19.1%) 1
The advantage of sucralfate stems from its lack of effect on gastric pH, preventing bacterial overgrowth that occurs with acid-suppressing agents, according to the Intensive Care Medicine guidelines 1

The American College of Cardiology and Gastroenterology societies recommend sucralfate as an alternative therapy for peptic ulcer disease, with proton pump inhibitors (PPIs) being the first-line therapy 2, 3

For H. pylori-associated ulcers, the World Journal of Emergency Surgery recommends adding eradication therapy to the treatment regimen 4, 5

Modern guidelines, including those from the American College of Cardiology, generally recommend PPIs over sucralfate as first-line therapy for peptic ulcer disease 2, 6